Plain-English translation of NCT07265479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a new medication called tapinarof cream to treat atopic dermatitis (eczema) in very young children—babies between 3 and 23 months old. The study will compare the new treatment against a plain cream without medicine to see which one works better and is safe for this age group. Researchers want to understand if this medication can help reduce the itching and skin irritation that eczema causes in infants.
Eczema can be really uncomfortable for babies and stressful for families, but there aren't many treatment options specifically tested and approved for such young children. This trial aims to fill that gap by finding safe and effective ways to treat infant eczema.
You likely qualify if…
You likely don't qualify if…
Your baby will be randomly assigned to receive either the new medicated cream or a plain cream without medicine, applied once daily for up to 8 weeks. You won't know which cream your baby is getting at first (that's the blinded part), but the researchers will be monitoring your baby's skin closely during this time. After the first 8-week period, the study moves to an open-label phase where everyone knows what treatment they're receiving, and you'll continue applying the medication while the team tracks how well it's working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States